New York Eye and Ear Infirmary of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Ophthalmology, Weill-Cornell Medical Center, New York, NY, USA.
Surv Ophthalmol. 2024 Jan-Feb;69(1):34-41. doi: 10.1016/j.survophthal.2023.09.007. Epub 2023 Sep 28.
Fibroblast growth factor receptor (FGFR) inhibitors are an emerging class of small molecule targeted cancer drugs with promising therapeutic possibilities for a wide variety of malignancies. While ocular adverse events from FGFR inhibitors are reported in clinical trials, subsequent case studies continue to reveal new toxicities. Disease pathology affecting multiple parts of the eye has been reported, but the ocular surface and the retina are the most commonly encountered areas affected by FGFR inhibitors, manifesting as dry eye and FGFR inhibitor-associated retinopathy, respectively. Corneal thinning and melt is a rare but serious and potentially vision-threatening complication of FGFR inhibitor toxicity. Similarities between toxicities observed from other targeted cancer therapy drugs and FGFR inhibitors may help us understand underlying pathophysiological changes. The management of these adverse events requires close ophthalmologic follow-up and may require discontinuation of the offending agents in some cases.
成纤维细胞生长因子受体 (FGFR) 抑制剂是一类新兴的小分子靶向抗癌药物，对于多种恶性肿瘤具有广阔的治疗前景。尽管在临床试验中报告了 FGFR 抑制剂的眼部不良反应，但后续病例研究仍不断揭示出新的毒性。据报道，影响眼睛多个部位的疾病病理，但眼部表面和视网膜是最常受到 FGFR 抑制剂影响的区域，分别表现为干眼症和 FGFR 抑制剂相关性视网膜病变。角膜变薄和融化是 FGFR 抑制剂毒性的一种罕见但严重且潜在威胁视力的并发症。在其他靶向癌症治疗药物和 FGFR 抑制剂中观察到的毒性之间的相似性可能有助于我们理解潜在的病理生理变化。这些不良反应的管理需要密切的眼科随访，在某些情况下可能需要停止使用有问题的药物。
